Epithelial–immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis
GM Verstappen, S Pringle, H Bootsma… - Nature Reviews …, 2021 - nature.com
In primary Sjögren syndrome (pSS), the function of the salivary glands is often considerably
reduced. Multiple innate immune pathways are likely dysregulated in the salivary gland …
reduced. Multiple innate immune pathways are likely dysregulated in the salivary gland …
Fatigue in inflammatory rheumatic diseases: current knowledge and areas for future research
Fatigue is a complex phenomenon and an important health concern for many people with
chronic inflammatory rheumatic diseases, such as rheumatoid arthritis, psoriatic arthritis …
chronic inflammatory rheumatic diseases, such as rheumatoid arthritis, psoriatic arthritis …
A new molecular classification to drive precision treatment strategies in primary Sjögren's syndrome
P Soret, C Le Dantec, E Desvaux, N Foulquier… - Nature …, 2021 - nature.com
There is currently no approved treatment for primary Sjögren's syndrome, a disease that
primarily affects adult women. The difficulty in developing effective therapies is-in part …
primarily affects adult women. The difficulty in developing effective therapies is-in part …
Current and future therapies for primary Sjögren syndrome
R Seror, G Nocturne, X Mariette - Nature Reviews Rheumatology, 2021 - nature.com
Primary Sjögren syndrome (pSS) is a systemic autoimmune disease that is characterized by
a triad of symptoms that affect all patients (dryness, pain and fatigue). In addition, systemic …
a triad of symptoms that affect all patients (dryness, pain and fatigue). In addition, systemic …
Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial
R Felten, V Devauchelle-Pensec, R Seror… - Annals of the …, 2021 - ard.bmj.com
Objectives No immunomodulatory drug has been approved for primary Sjögren's syndrome,
a systemic autoimmune disease affecting 0.1% of the population. To demonstrate the …
a systemic autoimmune disease affecting 0.1% of the population. To demonstrate the …
Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial
AN Baer, JE Gottenberg, EW St Clair… - Annals of the …, 2021 - ard.bmj.com
Objectives To evaluate efficacy and safety of abatacept in adults with active primary
Sjögren's syndrome (pSS) in a phase III, randomised, double-blind, placebo-controlled trial …
Sjögren's syndrome (pSS) in a phase III, randomised, double-blind, placebo-controlled trial …
Autoantibodies targeting intracellular and extracellular proteins in autoimmunity
PD Burbelo, MJ Iadarola, JM Keller… - Frontiers in …, 2021 - frontiersin.org
Detecting autoantibodies provides foundational information for the diagnosis of most
autoimmune diseases. An important pathophysiological distinction is whether …
autoimmune diseases. An important pathophysiological distinction is whether …
Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure
S Arends, L de Wolff, JF van Nimwegen… - The Lancet …, 2021 - thelancet.com
Background Recent randomised controlled trials (RCTs) in primary Sjögren's syndrome
used the European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease …
used the European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease …
Autoimmunity in dry eye disease–an updated review of evidence on effector and memory Th17 cells in disease pathogenicity
Abstract The classic Th1/Th2 dogma has been significantly reshaped since the subsequent
introduction of several new T helper cell subsets, among which the most intensively …
introduction of several new T helper cell subsets, among which the most intensively …
The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus
R Giacomelli, A Afeltra, E Bartoloni, O Berardicurti… - Autoimmunity …, 2021 - Elsevier
Autoimmune diseases (AIDs) share similar serological, clinical, and radiological findings,
but, behind these common features, there are different pathogenic mechanisms, immune …
but, behind these common features, there are different pathogenic mechanisms, immune …